Automated vs Handheld Ultrasound for Breast Cancer Screening - The ASCO Post
This story deserves to be shared
Send it to someone who'd care, or post it on your networks.
A new study by Rauscher et al in the Journal of the American College of Radiology has found that automated breast ultrasound (ABUS) and handheld ultrasound (HHUS) had similar cancer detection rates in women with dense breasts, whereas ABUS had a lower false-positive rate. These data demonstrate that ABUS is a viable alternative to HHUS and can expand supplemental ultrasound screening capacity at radiology clinics, according to investigators.
There is increasing demand for ultrasound screening in addition to mammography following the enactment of state laws and federal rules requiring radiology clinics to inform women with dense breasts about the limitations of mammography. Because dense tissue and lesions both appear white on a mammogram, abnormalities can more easily go undetected.
This article is an excerpt. To read the full content, visit the original source. The ASCO Post
Related articles
Automated Breast Ultrasound Tied to Fewer False-Positives in Dense Breasts - Oncology Nursing News
News|Articles|October 15, 2026 ABUS matched handheld ultrasound on cancer detection in women with dense breasts while lowering recall and short-interval follow-up rates. Automated breast ultrasound (ABUS) detected breast cancer at a rate similar to handheld ultrasound (HHUS) in women with dense breasts while producing fewer abnormal interpretations, fewer false-positive initial assessments, and fewer recommendations for short-interval follow-up, according to an observational study published in the October 2026 issue of the Journal of the American College of Radiology. The analysis, drawn from more than 25,000 supplemental screening examinations in US community practice, was not designed to establish sensitivity or specificity, and ABUS may not be appropriate for every patient with dense breast tissue. According to the investigators and an accompanying news release, this is the first study to directly compare the screening performance of the 2 modalities in clinical practice in the United States. Why does supplemental ultrasound screening matter for patients with dense breasts?
Continuous glucose monitors help type 2 diabetes patients spend 5 more hours a day in healthy blood sugar range - Medical Xpress
Continuous glucose monitors (CGMs) could transform diabetes management for millions of Americans with type 2 diabetes who don't take insulin, according to findings published in the New England Journal of Medicine. The clinical trial found that adults using CGMs spent approximately five additional hours each day within their target blood sugar range compared with those receiving routine care. Nearly twice as many CGM users also achieved an A1c level below 7%, a common treatment goal for people with diabetes.
Wearing headphones during surgery may reduce nausea and vomiting afterward - Medical Xpress
Patients who wore noise-canceling headphones during minimally invasive gynecological surgery were significantly less likely to experience postoperative nausea and vomiting (PONV), suggest findings from a randomized clinical trial presented at the Anesthesiology 2026 annual meeting.
Kefah Mokbel: Can Whole-Genome Sequencing-Based ctDNA Monitoring Help Personalize Adjuvant Treatment? - Oncodaily
“Beyond Detecting Cancer Recurrence: Can Whole-Genome Sequencing-Based ctDNA Monitoring Help Personalize Adjuvant Treatment? An exciting new study published in The Oncologist highlights the clinical potential of Signatera Genome, a whole-genome sequencing (WGS)-based, tumor-informed circulating tumor DNA (ctDNA) assay, not only for detecting molecular residual disease (MRD), but also for potentially informing adjuvant treatment decisions.
0 comments
No comments yet. Be the first to share your thoughts!